IP Library Granted Patent US 8,076,097
Granted Patent B2
US 8,076,097 · App. 12/543,699 · Granted Dec 13, 2011

Imatinib immunoassay

Assignee: Saladax Biomedical Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,076,097
App. No.
12/543,699
Granted
Dec 13, 2011
Kind
B2
Abstract

Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.

Claims (16)

1. An immunoassay for detecting imatinib and its pharmacologically active salts in a sample comprising providing a mixture of a sample, an antibody selectively reactive with imatinib and its pharmacologically active salts and a conjugate of a carrier containing a polymer having either a reactive thiol or amino group with a compound of the formula:

or its pharmacologically active salts

wherein Y is an organic spacing group;

X is a terminal functional group capable of binding to said carrier through said amino or thiol group and;

p is an integer from 0 to 1;

causing the imatinib and its pharmacologically active salts in the sample and said conjugate to bind with said antibody and thereafter measuring the amount of said conjugate in said mixture which is bound or unbound to said antibody whereby the presence of imatinib or its pharmacologically active salts in the sample can be determined.

2. The process of claim 1 , wherein the sample is a human sample.

3. The immunoassay of claim 2 , wherein said antibody is generated from an immunogen comprising an immunogenic carrier containing a polymer having either a reactive thiol or amino group linked to a compound of the formula:

or its pharmacologically active salts.

wherein Y is an organic spacing group;

X is a terminal functional group capable of binding to said carrier through said amino or thiol group and;

p is an integer from 0 to 1.

4. The immunoassay of claim 2 , wherein the antibody or the conjugate is attached to a solid support.

5. The immunoassay of claim 4 , wherein the solid support is microtiter plates.

6. The immunoassay of claim 2 , wherein the solid support is nanoparticles.

7. The immunoassay of claim 1 wherein said antibody does not substantially bind to N-desmethyl imatinib.

Assignments (2)
SECURITY INTEREST Recorded Nov 17, 2015
From: SALADAX BIOMEDICAL, INC.
To: SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Reel/Frame 037126/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2009
From: SALAMONE, SALVATORE J.; COURTNEY, JODI BLAKE; VOLKOV, ALEXANDER
To: SALADAX BIOMEDICAL INC.
Reel/Frame 023184/0348 →
Continuity (1)
Related Publication 20110045608A1 · Feb 24, 2011